DNA and DNA-processing enzymes

This target category encompasses the genomic DNA and the specialized enzymes required for its replication and maintenance within activated, proliferating lymphocytes. Lymphocytes are particularly sensitive to the disruption of these processes because they rely heavily on de novo nucleotide synthesis pathways rather than salvage pathways during rapid clonal expansion (Janeway's Immunobiology, 9th ed.). Therapeutic agents targeting this system include antimetabolites like mycophenolate mofetil and azathioprine, which deplete nucleotide pools, as well as alkylating agents like cyclophosphamide that cause direct structural damage to the DNA template (StatPearls, 2023; PubChem). These drugs are widely utilized in the treatment of autoimmune disorders, the prevention of organ transplant rejection, and the management of lymphoid malignancies such as leukemia and lymphoma (NIH, 2022). The mechanism of action typically involves arresting the cell cycle at the S-phase or inducing apoptosis through the activation of DNA damage checkpoints (PubMed, PMID: 28847408). However, the lack of cell-type specificity often results in significant safety concerns, most notably myelosuppression and an increased risk of opportunistic infections (PubMed, PMID: 31536352). Monitoring of biomarkers such as absolute lymphocyte counts and specific genetic variants like TPMT is often required to optimize dosing and minimize toxicity (FDA). Despite these challenges, targeting DNA processing remains a fundamental strategy in clinical immunology and oncology.

Other names

DNA replication machineryLymphocyte DNA synthesis pathwayNucleic acid synthesis targets

Inhibition of de novo nucleotide synthesis, direct DNA alkylation, and interference with DNA polymerase or topoisomerase activity to arrest the cell cycle in lymphocytes.